跳至主要内容
临床试验/ACTRN12611000646943
ACTRN12611000646943招募中4 期

A multi-center, prospective, randomised controlled trial comparing the efficacy and safety of PRODISC-C (Registered Trade Mark) implant to anterior cervical discectomy and fusion (ACDF) surgery, in the treatment of symptomatic cervical disc disease (SCDD)

Synthes Asia Pacific0 个研究点目标入组 300 人开始时间: 2011年6月23日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • 1.Subjects with symptomatic cervical disc disease (SCDD) in only one vertebral level between C3-C7 defined as:
  • Neck or arm (radicular) pain; and/or a functional / neurological deficit with at least one of the following conditions confirmed by imaging (Computed Tomography scans, Magnetic Resonance Imagings or X-rays)
  • -Herniated nucleus pulposus
  • -Spondylosis (defined by the presence of osteophytes)
  • -Loss of disc height
  • 2.Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root compression in the face of conservative treatment.
  • 3.Neck Disability Index (NDI) score greater than or equal to 15/50 (30%) (Considered moderate disability).

排除标准

  • 1.More than one vertebral level requiring treatment (showing marked changes at a second level)
  • Marked cervical instability on resting lateral or flexion/extension radiographs:
  • a.translation greater than 3 mm and/or
  • b.greater than 11 degrees of rotational difference to that of either adjacent level .
  • 2.Radiographic confirmation of severe facet joint disease or degeneration.
  • 3.Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene.
  • Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma, e.g., by the radiographic appearance of fracture callus, malunion or nonunion.
  • 4.Severe spondylosis at the level to be treated as characterized by any of the following:
  • - Bridging osteophytes;
  • - A loss of disc height greater than 70%
  • - Absence of motion (<2 degrees).
  • 5.Neck or arm pain of unknown etiology.
  • 6.Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require
  • a Dual Energy X-ray Absorptiometry (DEXA) bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T-score < -2.5 (The World Health Organization definition of osteoporosis. )
  • 7.Paget’s disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed above).
  • 8.Severe diabetes mellitus requiring insulin management
  • 9.Pregnant
  • 10.Active infection - systemic or local.
  • 11.Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids).
  • 12.Rheumatoid arthritis or other autoimmune disease.
  • 13.Systemic disease including AIDS, HIV, hepatitis.
  • 14.Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
  • 15.Workers compensation or action compensation patients (at the surgeons discretion).
  • 16.Subjects involved in other trials within the last month, prior to screening.
  • 17.Subjects refused to agree to either ProDisc-C or Anterior Cervical Discectomy and Fusion (ACDF) treatment.

研究者

发起方
Synthes Asia Pacific

相似试验